Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRGO: Vuity BID in Presbyopia
NCT04983589Phase 3Completed
- Sponsor
- Allergan
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in presbyopia comparing Vuity BID with Vehicle BID (2 arms). Primary endpoint: Percentage of Participants Gaining 3 Lines or More in Mesopic, High-Contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) With No More Than 5-Letter Loss in Mesopic Corrected Distance… Started Sep 2021; status: completed.
02
Drugs
pilocarpine
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT04983589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983589.